These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 27745574)
21. Use of Lactulose in Hepatic Encephalopathy: Is It Time to Shift Targets? Sharma S; Chauhan A Clin Gastroenterol Hepatol; 2022 May; 20(5):e1220-e1221. PubMed ID: 34058412 [No Abstract] [Full Text] [Related]
22. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy. Ahire K; Sonawale A J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305 [TBL] [Abstract][Full Text] [Related]
23. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Huang E; Esrailian E; Spiegel BM Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657 [TBL] [Abstract][Full Text] [Related]
25. Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora. Weber FL Dig Dis; 1996; 14 Suppl 1():53-63. PubMed ID: 8872452 [TBL] [Abstract][Full Text] [Related]
26. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328 [TBL] [Abstract][Full Text] [Related]
28. Role of gut bacteria in the therapy of hepatic encephalopathy with lactulose and antibiotics. Dasarathy S Indian J Gastroenterol; 2003 Dec; 22 Suppl 2():S50-3. PubMed ID: 15025256 [TBL] [Abstract][Full Text] [Related]
31. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy? Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969 [TBL] [Abstract][Full Text] [Related]
32. [Long-term efficacy of lactulose in patients with subclinical hepatic encephalopathy]. Nie YQ; Zeng Z; Li YY; Sha WH; Ping L; Dai SJ Zhonghua Nei Ke Za Zhi; 2003 Apr; 42(4):261-3. PubMed ID: 12887812 [TBL] [Abstract][Full Text] [Related]
33. Can we ignore minimal hepatic encephalopathy any longer? Qadri AM; Ogunwale BO; Mullen KD Hepatology; 2007 Mar; 45(3):547-8. PubMed ID: 17326151 [No Abstract] [Full Text] [Related]
34. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What? Henderson PK; Herrera JL Clin Liver Dis; 2015 Aug; 19(3):487-95. PubMed ID: 26195203 [TBL] [Abstract][Full Text] [Related]
36. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy]. Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding. Aires FT; Ramos PT; Bernardo WM Rev Assoc Med Bras (1992); 2016; 62(3):243-7. PubMed ID: 27310548 [TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo lactose and lactulose effects on colonic fermentation and portal-systemic encephalopathy parameters. Uribe-Esquivel M; Moran S; Poo JL; Muñoz RM Scand J Gastroenterol Suppl; 1997; 222():49-52. PubMed ID: 9145447 [TBL] [Abstract][Full Text] [Related]
39. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides. Morgan MY Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474 [TBL] [Abstract][Full Text] [Related]